FreeCME

Emerging Strategies in Response Assessment and Treatment Goals for Patients with Chronic Myelogenous Leukemia

This webcast is jointly provided by A. Webb Roberts Center for CME of Baylor Health Care System and CancerNet.

For more information visit: www.cancernetus.com

Grantors:

Teva Pharmaceuticals
Novartis Pharmaceuticals Corporation

Scroll to the Bottom of this Information to Begin this Course

Release date: April 20, 2015

Valid through: April 20, 2016

Specialty: Hematology/Oncology

Topic: Chronic Myelogenous Leukemia (CML).

Media: Internet

Target Audience

This webcast is designed to meet the educational needs of hematologists/oncologists and other health care professionals who diagnose, treat, and manage patients with chronic myelogenous leukemia (CML).

Statement of Need/Program Overview

This webcast is intended to improve care of patients with CML by accelerating adoption of new guidelines and evidence-based practice change.  In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

This program consists of 4 continuing education activites.

Click the links below to review the activity launch pages containing full disclosure information.

 

Module 1 — 0.5 AMA PRA Category 1 Credits

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Evaluate the frontline therapy options for CML in Chronic Phase

 

Module 2 — 0.75 AMA PRA Category 1 Credits

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify response assessment  and management of tyrosine kinase inhibitors  resistance in the treatment of CML

 

Module 3 — 0.75 AMA PRA Category 1 Credits

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Summarize the impact of comorbidities and mutations on treatment decision in patients with CML

 

Module 4 —0.75 AMA PRA Category 1 Credits

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Understand the time-based response milestones and monitoring in patients with CML